Orphan drug funds to be used in testing new treatment for a rare but deadly form of stroke

November 18, 1999

Johns Hopkins scientists, using funds from a Food and Drug Administration Orphan Drug Award, will test a new way of treating intracerebral hemorrhage with intraventricular extension, a disorder that often hits younger people and African-Americans.

In a grant awarded to Johns Hopkins, investigators Neal Naff, assistant professor of neurosurgery, and Daniel Hanley, professor of neurology, neurosurgery and critical care medicine, will lead a group of 12 brain injury centers in a new form of treatment. The $600,000 grant will test the safety and efficacy of using very small doses of tissue plasminogen activator (TPA), a clot-buster, to speed the removal of blood from the middle of the brain.

There currently is no treatment for this form of stroke, which has a mortality rate of around 75 percent.

TPA is commonly used in cases of heart attacks and many strokes, according to Hanley. It has not been used for intraventricular hemorrhage thrombolysis yet.

Orphan drug awards are given by the U.S. Food and Drug Administration to study treatments for uncommon diseases that normally would not attract the attention of profit-driven drug companies.

While TPA is not an orphan drug, the treatment is an orphan application, Hanley says. Intracerebral hemorrhage with intraventricular extension strikes about 15,000 to 30,000 people a year. The disorder occurs when the pumping heart pushes the blood through the vessel walls into the tissue in the middle of the brain.

Most of the patients are rendered unconscious, Hanley says, and even in the best medical centers, mortality is high.

The only treatment is the use of a ventricular drain to remove the blood. In an earlier study, it was shown it takes as long as 10 days to remove all the blood, and the drain itself frequently clogs.

The study will test whether with very low doses of TPA, clogging is reduced and the speed blood of extraction is hastened.

A normal dose of TPA is 80 to 110 mg in the treatment of stroke. Hanley proposes to use much less, 1 to 3 mg, diluted in the patient's own spinal fluid and injected into the ventricle twice a day. Draining could commence an hour after administration.

"We have interesting and very provocative pilot data suggesting that if you get the blood out of the ventricular cavities, the patient's likelihood of mortality is significantly reduced," Hanley says.

"We can't investigate everything in one study," he says. "We're investigating whether the drug will work to clear the blood out. If we can demonstrate that, we have the basis to go on to ask whether the clearing of blood actually increases survival rate, whether the blood needs to be cleared out rapidly, or can it be drained slowly."

The study begins at the first of the year on 48 patients over a three-year period. "We have some hope we may come to important conclusions before three years," says Hanley.
-end-
The FDA's Orphan Products Web site is: www.fda.gov/orphan/index.htm

Johns Hopkins Medicine

Related Stroke Articles from Brightsurf:

Stroke alarm clock may streamline and accelerate time-sensitive acute stroke care
An interactive, digital alarm clock may speed emergency stroke care, starting at hospital arrival and through each step of the time-sensitive treatment process.

Stroke patients with COVID-19 have increased inflammation, stroke severity and death
Stroke patients who also have COVID-19 showed increased systemic inflammation, a more serious stroke severity and a much higher rate of death, compared to stroke patients who did not have COVID-19, according a retrospective, observational, cross-sectional study of 60 ischemic stroke patients admitted to UAB Hospital between late March and early May 2020.

'Time is vision' after a stroke
University of Rochester researchers studied stroke patients who experienced vision loss and found that the patients retained some visual abilities immediately after the stroke but these abilities diminished gradually and eventually disappeared permanently after approximately six months.

More stroke awareness, better eating habits may help reduce stroke risk for young adult African-Americans
Young African-Americans are experiencing higher rates of stroke because of health conditions such as high blood pressure, diabetes and obesity, yet their perception of their stroke risk is low.

How to help patients recover after a stroke
The existing approach to brain stimulation for rehabilitation after a stroke does not take into account the diversity of lesions and the individual characteristics of patients' brains.

Kids with headache after stroke might be at risk for another stroke
A new study has found a high incidence of headaches in pediatric stroke survivors and identified a possible association between post-stroke headache and stroke recurrence.

High stroke impact in low- and middle-income countries examined at 11th World Stroke Congress
Less wealthy countries struggle to meet greater need with far fewer resources.

Marijuana use might lead to higher risk of stroke, World Stroke Congress to be told
A five-year study of hospital statistics from the United States shows that the incidence of stroke has risen steadily among marijuana users even though the overall rate of stroke remained constant over the same period.

We need to talk about sexuality after stroke
Stroke survivors and their partners are not adequately supported to deal with changes to their relationships, self-identity, gender roles and intimacy following stroke, according to new research from the University of Sydney.

Standardized stroke protocol can ensure ELVO stroke patients are treated within 60 minutes
A new study shows that developing a standardized stroke protocol of having neurointerventional teams meet suspected emergent large vessel occlusion (ELVO) stroke patients upon their arrival at the hospital achieves a median door-to-recanalization time of less than 60 minutes.

Read More: Stroke News and Stroke Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.